VivArt-X develops synthetic support material for specific cell therapies. Our lead indication will revolutionize breast reconstructive surgery in women who have undergone breast tissue removal after breast cancer diagnosis. Approximately 50% of the 2.3 million breast cancer patients worldwide need cancerous tissue removal and require breast reconstructive surgery. The estimated global market of breast reconstructive surgery is 2.7 billion in 2021, with a CAGR of 10%.
Current breast reconstruction methods make use of toxic silicone implants, infection-prone autologous flap surgery or autologous fat grafting. Unfortunately, the injection of fat cells in this fat grafting procedure results in 70% of death cells within months, owing to bad cell engraftment and loss of blood supply. To overcome these complications multiple fat injections and surgery to remove inflamed tissue are needed.
VivArt-X offers a revolutionary synthetic, degradable support material together with autologous fat cells to achieve excellent cell engraftment, and as a result of that, personalized breast reconstruction and ultimately regeneration.
Our support material is based on synthetic components that can be tuned to the requirements of a specific cell type with respect to the mechanical and biological properties. Prof. Dankers has a track record in developing support materials to culture various single cell types, complex cell aggregates and organoids, a.o. derived from induced pluripotent stem cells. To show clinical validation of our first product we need an investment of 8M Euro. We are finalizing our feasibility studies. To start the development fase, we need a first investment of at least 500K Euro.
The team of VivArt-X combines expertise in biomedical engineering and (supramolecular) chemistry and has excellent experience with business development. VivArt-X technology is developed in the research group of Professor dr. dr. Patricia Dankers. She is the creator of the original idea and is co-founder of the company UPyTher. Dr. ir. Dan Jing Wu has a scientific and engineering background with entrepreneurship experience and developed the business plan.
Last updated: May 2022